US Stock Insider Trading | Adaptive disclosed two insider trading transactions on February 6

K-LinePoet · 2026-03-07T11:03:03+00:00

On February 6, 2026, Adaptive disclosed insider trading activity. Executive PISKEL KYLE bought 2,145 shares on February 4 and sold the same number of shares on the same day. Additionally, several other executives and directors also engaged in stock trading during this period. Adaptive Biotechnologies focuses on using the immune system for disease diagnosis and treatment.

K-LinePoet

2026-03-07 11:03:03

Abstract generation in progress

On February 6, 2026, Adaptive (ADPT) disclosed two insider trading transactions. Executive PISKEL KYLE purchased 2,145 shares on February 4, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Executive	PISKEL KYLE	February 4, 2026	Sell	2,145	18.46	$39,600
February 6, 2026	Executive	PISKEL KYLE	February 4, 2026	Buy	2,145	12.14	$26,000
February 4, 2026	Director	ROBINS CHAD M	February 2, 2026	Sell	125,000	18.44	$2,305,000
February 4, 2026	Executive	ROBINS HARLAN S	February 2, 2026	Sell	34,700	18.60	$644,800
February 4, 2026	Executive	ROBINS HARLAN S	February 3, 2026	Sell	8,120	19.00	$154,300
January 14, 2026	Executive	LO FRANCIS	January 12, 2026	Buy	7,723	12.14	$93,800
January 14, 2026	Executive	LO FRANCIS	January 12, 2026	Sell	79,600	17.73	$1,411,100
January 14, 2026	Executive	PISKEL KYLE	January 12, 2026	Buy	4,290	12.14	$52,100
January 14, 2026	Executive	PISKEL KYLE	January 12, 2026	Sell	4,290	18.00	$77,200
January 14, 2026	Executive	LO FRANCIS	January 12, 2026	Buy	14,200	3.99	$56,700

【Company Profile】

Adaptive Biotechnologies Corporation was incorporated in Washington State on September 8, 2009. The company is transforming disease diagnosis and treatment by leveraging the innate biology of the adaptive immune system, advancing the field of immuno-driven medicine. The company believes that the adaptive immune system is nature’s most precise method for diagnosing and treating most diseases, but its capabilities are not fully decoded and utilized by medicine. The company’s immunology platform uses proprietary technology to read multiple genetic codes of patients’ immune systems, enabling accurate detection and treatment of diseases. The platform captures these insights in a dynamic clinical immunomics database, which is based on computational biology and machine learning, used to develop and commercialize tailored clinical products and services for each patient.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes